# Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

> **NCT04588077** · PHASE4 · RECRUITING · sponsor: **Mercy Medical Center** · enrollment: 200 (estimated)

## Conditions studied

- Hepatitis B
- Cirrhosis, Liver
- Chronic Liver Disease

## Interventions

- **BIOLOGICAL:** Heplisav-B Injectable Product, 2-dose regimen
- **BIOLOGICAL:** Heplisav-B Injectable Product, 3-dose regimen

## Key facts

- **NCT ID:** NCT04588077
- **Lead sponsor:** Mercy Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-14
- **Primary completion:** 2028-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04588077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04588077, "Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04588077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*